1. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 1639–1646.
2. Wilkinson JD, Landy DC, Colan SD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin 2010; 6: 401–413.
3. Kay JD, Colan SD, Graham TP Jr. Congestive heart failure in pediatric patients. Am Heart J 2001; 142: 923–928.
4. Šamánek M, Slavík Z, Zbořilová B, et al. Prevalence, treatment,and outcome of heart disease in live-born children: A prospective analysis of 91,823 live born children. Pediatr Cardiol 1989; 10: 205–211.
5. Parr GVS, Blackstone EH, Kirklin JW. Cardiac performance and mortality early after intracardiac surgery in infants and young children. Circulation 1975; 51: 867–874.
6. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995; 92: 2226–2235.
7. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107: 996–1002.
8. van der Vorst MM, Kist JE, van der Heiiden AJ, et al. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs 2006; 8: 245–264.
9. Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation 2010; 122: 333–340.
10. Gisler F, Knirsch W, Harpes P, et al. Effectiveness of angiotensin-converting enzyme inhibitors in pediatric patients with mid to severe aortic valve regurgitation. Pediatr Cardiol 2008; 29: 906–909.
11. Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. Am Coll Cardiol 2000; 36: 270–275.
12. Calabro R, Pisacane C, Pacileo G, et al. Hemodynamic effect of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J 1999; 138: 955–961.
13. Alehan D, Ozkutlu S. Beneficial effect of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am Heart J 1998; 135: 598–603.
14. Patel AR, Shaddy RE. Role of beta-blocker therapy in pediatric heart failure. Ped Health 2010; 4: 45–58.
15. Ufer C, Germack R. Cross-regulation between beta 1- and beta 3-adrenoceptors following chronic beta-adrenergic stimulation in neonatal rat cardiomyocytes. Br J Pharmacol 2009; 158: 300–313.
16. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure. JAMA 2007; 298: 1171–1179.
17. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001, 138: 505–511.
18. Azeka E, Franchini Ramirez JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40: 2034–2038.
19. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002; 21: 906–909.
20. Buckhorn R, Hulpke-Wette M, Ruschewski W, et al. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol Young 2003; 13: 36–43.
21. Rusconi P, Gomez-Arin O, Rossique-Gonzales M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004; 23: 832–838.
22. Blume ED, Canter CE, Spicer R, et al. Prospective, single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27: 336–342.
23. Bajcetic M, Kokic Nikolic A, Djukic M, et al. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Ther 2008; 30: 702–714.
24. Albers S, Meibohm B, Mir TS, et al. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 2008; 65: 511–522.
25. BEST trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659–1667.
26. Dorn GW, Liggett SB. Mechanism of pharmacogenomic effect of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharm 2009; 76: 466–480.
27. Kaufman BD, Desai M, Reddy S, et al. Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Cardiac Fail 2008; 14: 760–767.
28. Zaugg M, Schaub MC, Pasch T, et al. Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth 2002; 88: 101–123.
29. Furck AK, Desai A, Rodrigues W, et al. Beta-receptor blocking medication as a rescue treatment for severe postoperative myocardial diastolic dysfunction in infants. Cardiol Young 2011; 21: S158.
30. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefit in post-myocardial infarction: a meta-regression of randomised clinical trials. Eur Heart J 2007; 28: 3012–3019.
31. Mahmoud AB, Tantawy AE, Kouatli AA, et al. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg 2008; 7: 184–187.
32. Huang MH, Wu Y, Nguyen V, Rastogi S, et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther 2011; 25: 223–232.
33. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006; 139:686–694.